Presentations NCHIV 2016

Session 1: Preventing HIV
Chairs: Catherine Hankins & Marc van der Valk
09:10-09:40 Plenary: HIV prevention in Europe today: making it happen Sheena McCormack (University College London/Imperial College London)
09:40-09:50 Transmitted founder viruses escape HIV-1 restriction by Langerhans cells during sexual transmission Nina Hetoghs (AMC)
09:50-10:00 More participants prefer daily PrEP to event-driven PrEP: baseline characteristics in a Dutch PrEP Demonstration Project Elske Hoornenborg (GGD Amsterdam)
10:00-10:10 Informal PrEP use among MSM in Europe – first results from the EU Flash PrEP survey Kai Jonas (Maastricht University)
10:10-10:20 Risk compensation among HIV pre-exposure prophylaxis users: Evidence of decreasing condom use over nine months follow-up among men who have sex with men participating in the VicPrEP study, Melbourne John de Wit (Utrecht University)
Session 2: Challenging issues in HIV care
Chairs: Eline op de Coul & Guido van den Berk
11:00-11:20 The HIV epidemic in the Netherlands: an update Peter  Reiss (Stichting HIV Monitoring; AIGHD; AMC-UvA)
11:20-11:50 Plenary: Stigma associated with HIV Alexander Pastoors (Hiv Vereniging)
11:50-12:00 Immune activation by HIV-1 enhances sexual transmission of HCV Bernadien Nijmeijer (AMC)
12:00-12:10 Successful implementation of HCV treatment in two large HIV clinics in Amsterdam: HCV treatment cascade of care Job Saris (AMC)
12:10-12:20 Intensive Hepatitis C monitoring in previously HCV infected HIV-positive MSM is a cost saving method to reduce the HCV epidemic Stephanie Popping (Erasmus MC)
12:20-12:30 High prevalence of HIV drug resistance among newly diagnosed infants aged < 18 months: results from a nationwide surveillance in Nigeria Kim Sigaloff (AIGHD)
Session 3: Optimising the HIV care continuum
Chairs: Suzanne Geerlings & Maarten Schim van der Loeff
13:50-14:00 Integrase inhibitor use is an independent risk factor for immune reconstitution inflammatory syndrome (IRIS) in HIV-1 late presenters in the Dutch ATHENA cohort Ingeborg Wijting (Erasmus MC)
14:00-14:10 Incidence and risk factors for venous thrombotic events in HIV-infected patients: Data from the Dutch nationwide ATHENA cohort study Casper Rokx (Erasmus MC)
14:10-14:20 Estimating the HIV epidemic on a local level: the HIV care continuum in Amsterdam Ard van Sighem (Stichting HIV Monitoring)
14:20-14:30 Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: A randomized multicenter, non-inferiority clinical trial (DOMONO) Ingeborg Wijting (Erasmus MC)
14:30-15:00 Plenary: HIV treatment guidelines today and in the next 10 years Roy Gulick (Weill Medical College, Cornell University, USA)
Session 4: The road to cure
Chairs: Tokameh Mahmoudi & Daniel Kuritzkes
15:40-16:10 Plenary:  HIV persistence: implications for long-term complications in treated HIV disease and for achieving a cure Steven Deeks (University of California, San Francisco, USA)
16:10-16:20 Identifying acute HIV infection: implementation of a rapid diagnostic and referral trajectory including point-of-care HIV-RNA testing at the Public Health Service of Amsterdam Maartje Dijkstra (GGD Amsterdam)
16:20-16:30 Viral dynamics and post-mortem analysis of HIV-1 Reservoir after Allogeneic Transplantation using Stem Cells with a nonfunctional CCR5 (CCR5?32) co-receptor (work within the IciStem-project, formerly known as EpiStem) Kobus Bosman (UMC Utrecht)
16:30-16:40 Cell-associated HIV-1 unspliced RNA level predicts both time to virological suppression and duration of post-treatment virological control in patients treated with temporary early ART Alexander Pasternak (AMC)
16:40-16:50 A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape Femke Wolters (UMC Utrecht)
A bright future for Dutch HIV research
17:00-17:20 Aids Fonds ‘High-risk, high-gain’ elevator pitches